MCRB (Seres Therapeutics) Cyclically Adjusted FCF per Share: $-29.70 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MCRB Seres Therapeutics Inc MCRB
13 GF Score
Price $4.76
! 5 Warning Signs
View Full Analysis

What is Seres Therapeutics Cyclically Adjusted FCF per Share?

Seres Therapeutics MCRB -4.80% 13 Cyclically Adjusted FCF per Share is $-29.70 as of Jun. 2026. GuruFocus rates MCRB with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Seres Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was $-2.298. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-29.70 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-27), Seres Therapeutics's current stock price is $4.76. Seres Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-29.70. Seres Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Seres Therapeutics  (NAS:MCRB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Seres Therapeutics Cyclically Adjusted FCF per Share Related Terms


Seres Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Seres Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seres Therapeutics Cyclically Adjusted FCF per Share Chart

Seres Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -27.25 -28.95 -23.79

Seres Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.33 -24.58 -23.79 -31.35 -29.70

MCRB vs IBO, TIL, ATYR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Seres Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seres Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


MCRB
13GF Score
Seres Therapeutics Inc MCRB
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seres Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Seres Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-2.298/333.9520*333.9520
=-2.298

Current CPI (Jun. 2026) = 333.9520.

Seres Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -8.562 241.428 -11.843
201612 -13.128 241.432 -18.159
201703 -13.824 243.801 -18.936
201706 -13.335 244.955 -18.180
201709 -2.012 246.819 -2.722
201712 -10.505 246.524 -14.231
201803 -13.646 249.554 -18.261
201806 -12.974 251.989 -17.194
201809 -11.550 252.439 -15.280
201812 6.293 251.233 8.365
201903 -15.943 254.202 -20.945
201906 -5.374 256.143 -7.006
201909 -5.267 256.759 -6.850
201912 -4.070 256.974 -5.289
202003 -6.869 258.115 -8.887
202006 -7.038 257.797 -9.117
202009 -6.208 260.280 -7.965
202012 -3.971 260.474 -5.091
202103 -6.739 264.877 -8.496
202106 -9.219 271.696 -11.331
202109 26.043 274.310 31.705
202112 -11.635 278.802 -13.937
202203 -15.060 287.504 -17.493
202206 -11.285 296.311 -12.719
202209 -9.930 296.808 -11.173
202212 -9.005 296.797 -10.132
202303 -12.816 301.836 -14.180
202306 9.974 305.109 10.917
202309 -9.519 307.789 -10.328
202312 -7.434 306.746 -8.093
202403 -4.832 312.332 -5.166
202406 -5.268 314.175 -5.600
202409 -4.561 315.301 -4.831
202412 -4.550 315.605 -4.815
202503 3.084 319.799 3.220
202506 -1.540 322.561 -1.594
202509 0.251 324.800 0.258
202512 -1.594 324.054 -1.643
202603 -1.707 330.213 -1.726
202606 -2.298 333.952 -2.298

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-29.70 mean?
Seres Therapeutics (MCRB) has a Cyclically Adjusted FCF per Share of $-29.70 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Seres Therapeutics and its competitors.
Is Seres Therapeutics' Cyclically Adjusted FCF per Share too high?
Seres Therapeutics' current Cyclically Adjusted FCF per Share is $-29.70. Overall, Seres Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Seres Therapeutics' Cyclically Adjusted FCF per Share compare to IBO and TIL?
Seres Therapeutics' Cyclically Adjusted FCF per Share of $-29.70 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Seres Therapeutics and its competitors. Seres Therapeutics's current Cyclically Adjusted FCF per Share is $-29.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seres Therapeutics stock overvalued right now?
Seres Therapeutics (MCRB) has a current Cyclically Adjusted FCF per Share of $-29.70. The current Cyclically Adjusted FCF per Share is $-29.70. Seres Therapeutics' overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Seres Therapeutics (MCRB), the current Cyclically Adjusted FCF per Share is $-29.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seres Therapeutics Business Description

Other Exchanges 1S90:Germany
Address 101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
13GF Score

Get the complete analysis for MCRB

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.76
Price